Posted by Michael Wonder on 27 Jul 2016
EMA publishes EPAR for Qtern (saxagliptin hydrochloride with dapagliflozin propanediol monohydrate)
27 July 2016 - The EMA has published an EPAR for AstraZeneca's Qtern.
The European Commission approved Qtern on 15 July 2016 for the use by adults aged 18 years and older with type 2 diabetes mellitus:
- to improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of Qtern do not provide adequate glycaemic control,
- when already being treated with the free combination of dapagliflozin and saxagliptin
Read EPAR for Qtern
Posted by:
Michael Wonder